Low COX2 in tumor and upregulation in stroma mark laryngeal squamous cell carcinoma progression
Version of Record online: 24 JUN 2009
Copyright © 2009 The American Laryngological, Rhinological, and Otological Society, Inc.
Volume 119, Issue 9, pages 1723–1729, September 2009
How to Cite
Kourelis, K., Vandoros, G., Kourelis, T., Papadas, T., Goumas, P. and Sotiropoulou-Bonikou, G. (2009), Low COX2 in tumor and upregulation in stroma mark laryngeal squamous cell carcinoma progression. The Laryngoscope, 119: 1723–1729. doi: 10.1002/lary.20569
- Issue online: 27 AUG 2009
- Version of Record online: 24 JUN 2009
- Manuscript Accepted: 5 MAY 2009
- Medical School of Patras, Greece
- cancer progression;
Invasive squamous cell carcinomas (SCC) of the larynx, like most solid tumors, are surrounded by a reactive stroma, in which cancer associated fibroblasts (CAFs) are the predominant cell type. This mesenchymal reaction may affect cancer progression multiply. The proinflammatory enzyme cyclooxygenase-2 (COX-2) has been correlated with head and neck cancer. This study aims to explore the impact of epithelial and stromal COX-2 expression on SCC behavior.
Retrospective case review study performed in a tertiary health center institution.
Double immunohistochemistry of COX-2 and the CAF marker α-smooth muscle actin (α-SMA) was utilized in 97 laryngeal cancer patients. Follow-up data were collected in 52 cases.
Low COX-2 immunostaining in cancer cells was associated with advanced grade (P = .044) and shorter recurrence-free period (P = .035). CAF expression was positively correlated with the grade of the infiltrating tumor (P = .030).
In laryngeal SCCs, COX-2 may exert its deleterious effect by alterations in the tumor microenvironment. CAF-derived, COX-2-mediated paracrine influences on malignant cells possibly facilitate cancer progression. Overlooking the stromal remodeling could account for unsuccessful treatments of epithelial neoplasms. Laryngoscope, 2009